Treatment of polycystic ovary syndrome with insulin-lowering agents (Q44084386)

29 November 2017

title

Treatment of polycystic ovary syndrome with insulin-lowering agents (English)

1 reference

polycystic ovary syndrome

29 November 2017

main subject

1 reference

1 reference

1 reference

Ping Wang

1 reference

29 November 2017

Charles J Glueck

1 reference

29 November 2017

Patricia Streicher

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Expert Opinion on Pharmacotherapy

29 November 2017

published in

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

1177-1189

1 reference

Advances in the treatment of polycystic ovary syndrome

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Menstrual Cyclicity After Metformin Therapy in Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Insulin-lowering drugs in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Relationships of plasma C-peptide and gender to the urinary excretion of inositols in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin in management of pregnant insulin-independent diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Genetic hypofibrinolysis in complicated pregnancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The prevalence of polycystic ovaries in women with a history of gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The prevalence of polycystic ovaries in women with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Oral hypoglycaemic agents in 118 diabetic pregnancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The effect of the increasing prevalence of maternal obesity on perinatal morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

The thrifty genotype in type 2 diabetes: an unfinished symphony moving to its finale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Diabetes. Dialogue between muscle and fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Heritability and the risk of developing androgen excess

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Insulin resistance as a predictor of age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Cardiovascular risk in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Polycystic ovary syndrome is associated with endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Anti-androgens for the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.8.1177

10.1517/14656566.3.8.1177

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference